signalling pathway regulating proliferation and self-renewal of colonic epithelial cells 29, 30 . Besides FZD2, an unusual group of high-ranking hits are subunits of the endoplasmic reticulum membrane protein complex (EMC) 31, 32 .
To validate the screening results, we generated UGP2 −/− , CSPG4 −/− , FZD2 −/− and EMC4 −/− HeLa cell lines using the CRISPR-Cas9 approach ( Supplementary Table 1 ). Two additional knockout cells were also generated and examined: sphingomyelin synthase 1 (SGMS1 −/− ) and interleukin-1 receptor accessory protein-like 2 (IL1RAPL2 −/− ) (Fig. 1c) . These cells were challenged with either TcdB or TcdB using the cytopathic cell-rounding assay 1 (Extended Data Fig. 3a, b ). UGP2 −/− cells were highly resistant (~3,000-fold) to both TcdB and TcdB 1-1830 compared with wild-type HeLa cells ( Fig. 2a and Supplementary Table 2 ). CSPG4 −/− cells showed increased resistance to TcdB (~240-fold), but not to TcdB . FZD2 −/− and EMC4 −/− cells both showed increased resistance (~15 and ~11-fold, respectively) to TcdB 1-1830 , but not to TcdB. SGMS1 −/− and IL1RAPL2 −/− cells did not show significant changes in sensitivity to toxins under our assay conditions. Increased resistance of UGP2 −/− , CSPG4 −/− , FZD2 −/− and EMC4 −/− cells was further confirmed by immunoblot analysis for glucosylation of RAC1, a small GTPase (Extended Data Fig. 3c ).
CSPG4 is a CROP-dependent TcdB receptor
We next focused on CSPG4 and FZD2 as potential TcdB receptors. Binding of TcdB to CSPG4 −/− cells was reduced compared with wildtype HeLa cells ( Fig. 2b ). Ectopic expression of rat CSPG4 restored were quantified using the cytopathic cell-rounding assay (see Extended Data Fig. 3 ) and normalized to wild-type (WT) HeLa cells as fold of resistance. The experiments were repeated three times. b, c, Immunostaining analysis showed that TcdB binding (10 nM, 10 min) to CSPG4 −/− cells was reduced (b). Ectopic expression of rat CSPG4 increased binding of TcdB. Transfection of FZD2 also increased TcdB binding to CSPG4 −/− cells (c). Scale bar, 20 μm. DIC, differential interference contrast. d, Ectopic expression of CSPG4 or FZD2 restored TcdB entry into CSPG4 −/− cells, resulting in cell rounding (5 pM, 3 h). Green fluorescent protein (GFP)marked transfected cells. Scale bar, 50 μm. e, A schematic illustration of FZD (top). Fc-tagged FZD2-CRD binds to GST-tagged TcdB 1501-2366 , but not to GST-tagged CROPs. f, g, FZD2-CRD prevented TcdB (300 pM, 3 h) entry into CSPG4 −/− cells, measured by the cell-rounding assay (f) and glucosylation (gluc.) of RAC1 (g). Human IgG1-Fc (hIgG1-Fc) is a control. h, Transfection of either FZD1, 2 or 7 increased TcdB binding (10 nM, 10 min) to CSPG4 −/− cells, assayed by immunoblot analysis of cell lysates. Actin is a loading control. i, The sensitivities of FZD1 −/− , FZD2 −/− , FZD7 −/− and FZD1/2/7 −/− cells to TcdB and TcdB 1-1830 were analysed as described in a. j, Ectopic expression of FZD1, 2 or 7 restored TcdB 1-1830 entry into FZD1/2/7 −/− cells (300 pM, 3 h). Scale bar, 50 μm. k, Characterization of TcdB binding to Fc-tagged CRDs of FZD1, 2, 5 and 7 using the BLI assay (see Supplementary Table 3 for K d analysis). Representative images are from one of three independent experiments. Error bars indicate mean ± standard deviation (s.d.), n = 6, *P < 0.005, t-test.
binding and entry of TcdB ( Fig. 2b, d ). TcdB binds directly to purified rat CSPG4 extracellular domain fragments (CSPG4-EC) independent of the chondroitin sulfate glycan in CSPG4 (Extended Data Fig. 4a, b ). These results are consistent with a previous report 16 . However, contrary to the previous suggestion that CSPG4 does not bind to the CROPs 16 , we conclude that the CROPs are essential for TcdB binding to CSPG4 because: (1) TcdB 1-1830 does not bind to either purified CSPG4-EC or CSPG4 expressed on cell surfaces (Extended Data Fig. 4b , c); (2) CSPG4 −/− cells showed similar levels of sensitivity to TcdB 1-1830 as wild-type cells (Fig. 2a ); and (3) the CROPs are capable of competing with TcdB for binding to CSPG4 on cell surfaces (Extended Data Fig. 4d, e ). We note that the previous study used TcdB 1851-2366 as the CROPs 16 . Recent structural studies confirmed that the CROP region starts around residue 1834 instead of 1851 (ref. 33 ). Here we used fulllength CROPs (residues 1831-2366). It is possible that the 1831-1850 region is required for TcdB binding to CSPG4.
FZDs are CROP-independent receptors
Transfecting CSPG4 −/− cells with FZD2 also increased binding of TcdB ( Fig. 2c ) and restored entry of TcdB into CSPG4 -/cells ( Fig. 2d ), suggesting that FZD2 is an alternative receptor. In contrast to CSPG4, ectopically expressed FZD2 increased binding of TcdB and TcdB 1501-2366 on cell surfaces, but not the CROPs (Extended Data Fig. 4c , f), suggesting that it is a CROP-independent receptor. FZD2 is a seven-pass transmembrane protein and contains a sole distinct extracellular domain known as the CRD ( Fig. 2e) 29 . Consistently, recombinant Fc-tagged FZD2-CRD binds directly to glutathione S-transferase (GST)-tagged TcdB 1501-2366 , but not to the CROPs in pulldown assays ( Fig. 2e ).
It is possible that CSPG4 is expressed at a much higher level than FZD2 in HeLa cells, which may explain why TcdB binding to CSPG4 −/− cells is barely detectable using immunostaining and immunoblot assays. Notably, TcdB can enter CSPG4 −/− cells at picomolar concentrations, as detected by the sensitive cytopathic cell-rounding assay (Fig. 2f ). Such entry is blocked by recombinant FZD2-CRD in a dose-dependent manner, as evidenced by a lack of cell rounding and RAC1 glucosylation ( Fig. 2f, g ), suggesting that endogenous FZD2 mediates TcdB binding and entry in CSPG4 −/− cells.
The FZD family includes ten members (FZD1-10) in humans 29 . The ectopic expression of FZD1, 2 and 7 each increased binding of TcdB to CSPG4 −/− cells ( Fig. 2h and Extended Data Fig. 5a ), probably because the CRDs of FZD1, 2 and 7 share ~98% sequence similarity (Extended Data Fig. 5b ) 29 . Consistently, FZD7-CRD, but not FZD8-CRD, when expressed on cell surfaces via a fused glycophosphatidylinositol (GPI) anchor, mediated strong binding of TcdB to cells (Extended Data Fig. 5c ).
HeLa cells express multiple FZDs 34 . We next generated FZD1 and FZD7 single-knockout HeLa cells, as well as FZD1/2/7 triple-knockout cells. FZD1/2/7 −/− cells exhibited normal growth rates, probably because HeLa cells still express other FZDs. FZD1 −/− and FZD7 −/− cells showed reductions in sensitivity to TcdB 1-1830 similar to those of FZD2 −/− cells ( Fig. 2i ). FZD1/2/7 −/− cells were highly resistant to TcdB 1-1830 (~300-fold), confirming that FZD1, 2 and 7 all contribute to TcdB 1-1830 entry into HeLa cells. Transfection of FZD1, 2 or 7 restored TcdB 1-1830 entry into FZD1/2/7 −/− cells ( Fig. 2j ). FZD1/2/7 −/− cells also become ~10-fold more resistant to full-length TcdB than wild-type cells ( Fig. 2i ), indicating that endogenous FZD1, 2 and 7 are responsible for a portion of TcdB entry into wild-type HeLa cells. FZD1/2/7 −/− cells showed the same level of sensitivity to TcdA as wildtype cells (Extended Data Fig. 5d ), confirming that the resistance of FZD1/2/7 −/− cells is specific to TcdB.
We further quantified the binding kinetics between CRDs of FZD1, 2, and 7 and TcdB using the bio-layer interferometry (BLI) assay. The results revealed a single binding site with low nanomolar affinities (dissociation constant (K d ) = 32 nM for FZD1, 19 nM for FZD2, and 21 nM for FZD7) (Fig. 2k , Extended Data Fig. 5e and Supplementary   Table 3 ). Furthermore, FZD2-CRD showed the same binding affinity to TcdB 1-1830 (K d = 17 nM) as to full-length TcdB (Extended Data Fig. 5f ). FZD5-CRD also binds to TcdB when measured by the sensitive BLI assay, but with a much weaker affinity than FZD1, 2 and 7 (K d = 670 nM) ( Fig. 2k and Extended Data Fig. 5e ). It is possible that additional FZD family members may function as low-affinity receptors for TcdB.
The finding that EMC4 −/− cells showed a similar level of toxin resistance as FZD2 −/− cells is also consistent with FZDs being TcdB receptors ( Fig. 2a ). Although its function remains to be established, the EMC appears to be critical for the folding/stability of multi-transmembrane proteins 35, 36 . Consistently, expression of transfected FZD1, 2 or 7 was reduced in EMC4 −/− cells compared with wild-type cells (Extended Data Fig. 5g , h).
CSPG4 versus FZDs in cell lines
We next addressed whether TcdB is capable of simultaneous binding to both CSPG4 and FZDs. As shown in Extended Data Fig. 6a , FZD2-CRD binds to TcdB pre-bound by immobilized CSPG4-EC on the microtitre plate, confirming that CSPG4 and FZDs do not compete with each other for binding to TcdB.
We then examined the receptors responsible for TcdB entry in HT-29 and Caco-2 cells, which are known to express multiple FZDs 37 . FZD2-CRD protected both HT-29 and Caco-2 from TcdB 1-1830 ( Fig. 3a, b ), suggesting that FZDs are functional receptors in these two cell lines. Interestingly, CSPG4 is expressed at high levels in HeLa, at much lower levels in HT-29, and is undetectable in Caco-2 cells ( Fig. 3c ). Consistently, CSPG4-EC alone was sufficient to reduce TcdB entry into HeLa cells, whereas a combination of CSPG4-EC and FZD2-CRD was required to reduce TcdB entry into HT-29 cells, and FZD2-CRD alone protected Caco-2 cells ( Fig. 3d and Extended Data Fig. 6b ). These data suggest that CSPG4 and FZDs represent non-competing TcdB receptors, each capable of mediating binding and entry of TcdB. Their particular contribution in a given cell type may depend on their expression levels.
We also tested the potential role of PVRL3. Ectopically expressed PVRL3 did not increase either binding or entry of TcdB into CSPG4 −/− HeLa cells (Extended Data Fig. 7a, b ). The recombinant ecto-domain of PVRL3 failed to protect Caco-2 cells from TcdB in the cytopathic cell-rounding assay, whereas FZD2-CRD protected cells (Extended Data Fig. 7c ). Thus, PVRL3 is probably not a relevant receptor for the cytopathic effect of TcdB in HeLa and Caco-2 cells.
FZDs are TcdB receptors in colonic organoids
To determine the receptors that mediate TcdB entry into the colonic epithelium, we first used colonic organoids, an in vitro 'mini-gut' model that recapitulates many important features of normal colonic epithelium 38 . Exposure to TcdB caused dose-dependent atrophy and death of organoids, which was quantified using a viability assay ( Fig. 4a ). We found that TcdB 1-1830 and TcdB were equally potent, suggesting that CSPG4 is not a relevant receptor in colonic organoids (Extended Data Fig. 8a ). It has been reported that CSPG4 is not expressed in the colonic epithelium 17 , which was confirmed by immunoblot analysis of colonic organoids and isolated mouse colonic epithelium (Extended Data Fig. 8b ).
We next used colonic organoids cultured from FZD7-knockout mice, combined with adenovirus-mediated knockdown of FZD1 and FZD2 (Extended Data Fig. 8c, d ). FZD7 is critical for maintaining intestinal organoids, but FZD7 −/− organoids can be cultured in the presence of CHIR99021, a small-molecule inhibitor of glycogen synthase kinase-3 (GSK3), which activates Wnt/β-catenin signalling downstream of FZDs 39 . FZD7 −/− organoids showed threefold more resistance to TcdB than wild-type organoids (Fig. 4b ). Further knockdown of FZD1/2 in FZD7 −/− organoids yielded ninefold greater resistance to TcdB than wild-type organoids (Fig. 4b) , demonstrating that FZDs are relevant TcdB receptors in colonic organoids.
As both TcdB and Wnt bind to the FZD-CRD, we examined whether TcdB binding competes with Wnt and inhibits Wnt signalling. We used a non-toxic TcdB fragment (residues 1114-1835), which contains the FZD-binding region but not the enzymatic domain of TcdB. This fragment blocked WNT3A-mediated signalling in 293T cells in a dose-dependent manner, demonstrated by the TOPFLASH/TK-Renilla dual luciferase reporter assay ( Fig. 4c and Extended Data Fig. 9a ), as well as by phosphorylation levels of LRP6 (a FZD co-receptor) and DVL2 (a downstream Wnt signalling component) (Extended Data Fig. 9b ) 29 . TcdB 1114-1835 did not glucosylate small GTPases in colonic organoids (Extended Data Fig. 9c ), yet it inhibited organoid growth and induced death ( Fig. 4d and Extended Data Fig. 9d, e ). The death of colonic organoids was rescued by CHIR99021, demonstrating that the effect of TcdB 1114-1835 is due to blockage of Wnt signalling. These data raised the intriguing possibility that binding of TcdB to FZDs may directly contribute to disruption of the colon epithelium by inhibiting Wnt signalling.
FZDs are TcdB receptors in colonic epithelium
Finally, we examined the colonic epithelium in vivo. Immunohistochemistry (IHC) analysis showed that FZD2 and FZD7 are expressed in mouse and human colonic epithelium (Fig. 5a, b and Extended Data Fig. 10a-f ). In contrast, CSPG4 is predominantly expressed in the multi-nucleated intestinal sub-epithelial myofibroblasts (ISEMFs) and is not detectable in the colonic epithelium ( Fig. 5c and Extended Data Fig. 10c ), which is consistent with a previous report 17 .
As TcdB is released into the lumen of the colon during C. difficile infection, we developed a model in which we injected TcdB directly into the lumen of ligated colon segments in mice ( Fig. 5d ), which resulted in binding and entry of TcdB into the colonic epithelium ( Fig. 5e ). Co-injection of FZD2-CRD largely abolished binding of TcdB ( Fig. 5e ), suggesting that FZDs are the dominant receptors in the colonic epithelium.
To verify further the role of FZDs in vivo, we turned to FZDknockout mouse models. FZD2/7 double-knockout mice are embryonic lethal, and FZD2 -/mice also displayed developmental defects 40 . FZD7 −/− mice appear to develop normally and exhibit no overt intestinal defects under basal conditions 39, 40 . Thus, we chose FZD7 −/− mice to assess whether a loss of a major colonic FZD member may reduce TcdB toxicity in vivo. To focus the analysis on the colonic epithelium and avoid the potential effects of TcdB entry into CSPG4-expressing ISEMFs, we used TcdB 1-1830 and injected the toxin into the lumen of ligated colon segments of live mice. After an 8-h incubation period, fluid accumulation was observed in wild-type mice, but was significantly reduced in FZD7 −/− mice ( Fig. 5f ). Histological scoring revealed extensive disruption of the epithelium, inflammatory cell infiltration and oedema in wild-type mice, but much less in FZD7 −/− mice ( Fig. 5g and Extended Data Fig. 10g ). To assess epithelial integrity further, we performed immunofluorescent analysis on colonic sections for the cell-cell junction markers claudin-3 and ZO-1. Both markers were extensively disrupted in wild-type mice after exposure to TcdB 1-1830 but remained largely intact in FZD7 −/− mice ( Fig. 5h and Extended Data Fig. 10h ). Together, these data demonstrate that FZDs are physiologically relevant receptors for TcdB in the colonic epithelium in vivo.
Discussion
Our findings support a previously proposed two-receptor model for TcdB 25 , but with a notable amendment: FZDs and CSPG4 may act as receptors in different cell types. CSPG4 is expressed in the ISEMFs, which are involved in diverse processes from wound healing to inflammation 41 . Although the role of ISEMFs in C. difficile infection remains to be established, it is conceivable that targeting these cells by TcdB could contribute to disease progression after FZD-mediated disruption of the colonic epithelium.
Our unbiased genome-wide screens revealed multiple host factors involved in all major steps of toxin actions, from receptors (FZDs and CSPG4) to acidification in endosomes (vacuolar-type H + -ATPase) 42,43 , to enzymatic activity in the cytosol (UGP2) (Extended Data Fig. 10i ). Many other top-ranking hits remain to be validated, such as FBXO11 and enzymes involved in phospholipid metabolism/signalling, FZD7 −/− plus FZD1/2-knockdown (KD) organoids exposed to TcdB (0.5 pM, 3 days). Right, viability of organoids exposed to TcdB for 3 days was quantified by the MTT assay. n = 6, *P < 0.005, t-test. b, The halfmaximum inhibitory concentration (IC 50 ; the TcdB concentration that results in 50% viability after 3 days) of wild-type, FZD7 −/− and FZD7 −/− plus FZD1/2-knockdown organoids were quantified as described in a. n = 8, *P < 0.005, one-way analysis of variance (ANOVA including phosphatidylinositol 5-phosphate 4-kinase (PIP4K2B), phosphatidylinositol 4-kinase (PI4KB) and phospholipase C (PLCG1) (Extended Data Fig. 10i ).
Our screen identified many key players in Wnt signalling pathways, including APC, GSK-3β, WNT5A and LRP6 (Extended Data Fig. 10i ). It has been suggested that TcdA attenuates Wnt signalling in cells, although the effects appear to be indirect, largely due to deactivation of Rho GTPase by TcdA 44 . Wnt signalling is particularly important for maintaining colonic stem cells 30, 45 , which continuously give rise to new colonic epithelial cells. The health of these stem cells is critical for self-renewal and repair of the colonic epithelium, which has an extraordinarily fast turnover rate 45 . Our findings suggest that colonic stem cells are a major target of TcdB. The potential role of Wnt signalling inhibition in the pathogenesis of C. difficile infection, and the therapeutic potential of modulating Wnt signalling downstream of FZDs warrant further study. Finally, dysregulation of Wnt signalling pathways is associated with many cancers, particularly colorectal cancers 30, 46 . The receptor-binding domain of TcdB, or its homologues, may serve as valuable tools and potential therapeutics for targeting Wnt signalling pathways.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
Cell lines, antibodies and constructs. HeLa (H1, #CRL-1958), CHO (K1, #CCL-61), HT-29 (#HTB-38), Caco-2 (#HTB-37) and 293T (#CRL-3216) cells were originally obtained from ATCC. They tested negative for mycoplasma contamination, but have not been authenticated. The following mouse monoclonal antibodies were purchased from the indicated vendors: RAC1 (23A8, Abcam), non-glucosylated RAC1 (Clone 102, BD Biosciences), 1D4 tag (MA1-722, ThermoFisher Scientific), HA tag (16B12, Covance), β-actin (AC-15, Sigma), ZO-1 (339100, Life technology). Rabbit monoclonal IgG against human CSPG4 (ab139406) and rabbit polyclonal antibodies against FZD1 (ab150553), FZD2 (ab150477), FZD7 (ab51049), PVRL3 (ab63931) and claudin-3 (ab15102) were all purchased from Abcam. Rabbit monoclonal antibodies against DVL2 (30D2) and LRP6 (C5C7), and a rabbit polyclonal antibody against phosphorylated LRP6 (Ser1490) were all purchased from Cell Signaling. Chicken polyclonal IgY (#754A) against TcdB was purchased from List Biological Labs. Antibody validation is available on the manufacturers' websites. A rabbit polyclonal antibody against rodent CSPG4 and a construct expressing full-length rat CSPG4 (in pcDNA vector) were both generated in W. Stallcup's laboratory. 1D4-tagged full-length FZD1-10 constructs (in pRK5 vector) were originally generated in J. Nathans' laboratory (Baltimore, MD) and were obtained from Addgene. FZD7 and FZD8-CRD-Myc-GPI constructs were generously provided by J. Nathans and have been described previously 47 . Constructs expressing full-length human IL1RAPL2 and full-length PVRL3 were purchased from Vigene Biosciences. A construct expressing full-length mouse Syt II was described previously 48 . TcdB and other recombinant proteins. Recombinant TcdB (from C. difficile strain VPI 10463) and TcdA were expressed in Bacillus megaterium as previously described 49 and purified as His6-tagged proteins. TcdB 1-1830 was cloned into pHis1522 vector (MoBiTec) and expressed in B. megaterium. TcdB 1831-2366 , TcdB 1501-2366 and TcdB 1114-1835 were cloned into pGEX-6P-1 or pET28a vectors and purified as GST-tagged or His6-tagged proteins in Escherichia coli. Rat CSPG4-EC (pool (P)1 and P2) was expressed in HEK293 cells, purified from medium with DEAE-Sepharose columns, and eluted with a gradient buffer (NaCl from 0.2 to 0.8 M, 50 mM Tris-Cl, pH 8.6) as previously described 50 . Recombinant human proteins were purchased from ACRO Biosystems (IgG1 Fc and FZD2-CRD-Fc), R&D Systems (FZD1-CRD-Fc, FZD5-CRD-Fc and FZD7-CRD-Fc), Sino Biologics (PVRL3-EC), and StemRD (WNT3A). Generating stable HeLa-Cas9 cells and lentivirus sgRNA libraries. The human codon-optimized sequence of S. pyogenes Cas9 was subcloned from plasmid lenti-Cas9-Blast (Addgene #52962) into the pQCXIH retroviral vector (Clontech), which was used to generate retroviruses to transduce HeLa cells. Mixed stable cells were selected in the presence of hygromycin B (200 μg/ml, Life Technologies). Lentivirus sgRNA libraries were generated following published protocols using the human GeCKO v.2 sgRNA library (Addgene #1000000049) 19 . The GeCKO v.2 library is composed of two half-libraries (library A and library B). Each half-library contains three unique sgRNA per gene and was independently screened with toxins. Cells were transduced with lentivirus-packaged sgRNA library at a MOI of 0.2. Screening CRISPR libraries with TcdB and TcdB 1-1830 . For each CRISPR halflibrary of cells, 4 × 10 7 cells were plated onto two 15-cm culture dishes to ensure sufficient coverage of sgRNAs, with each sgRNA on average being represented about 650 times (that is, there are on average 650 cells transduced with the same sgRNA). This over-representation rate was calculated from titration plates that were set up in parallel with the library. These cells were exposed to either TcdB or TcdB 1-1830 for 48 h. Cells were then washed three times with PBS to remove loosely attached round-shaped cells. The remaining cells were re-seeded and cultured with normal medium without toxins until ~70% confluence. Cells were then subjected to the next round of screening with increased concentrations of toxins. Four rounds of screenings were carried out with TcdB (0.05, 0.1, 0.2 and 0.5 pM) and TcdB 1-1830 (5, 10, 20 and 50 pM). The remaining cells were harvested and their genomic DNA extracted using the Blood and Cell Culture DNA mini kit (Qiagen). DNA fragments containing the sgRNA sequences were amplified by PCR using primers lentiGP-1_F (AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG) and lentiGP-3_R (ATGAATACTGCCATTTGTCTCAAGATCTAGTTACGC). NGS (Illumina MiSeq) was performed by a commercial vendor (Genewiz). Generating HeLa knockout cell lines. The following sgRNA sequences were cloned into LentiGuide-Puro vectors (Addgene) to target the indicated genes: CCGGAGACACGGAGCAGTGG (CSPG4), GCGCTGCTGGGACATCGCCT (EMC4), ACCTTATACCACACAACATC (IL1RAPL2), TGCGAGCACTTCC CGCGCCA (FZD2), AGCGCATGACCACTACACTG (SGMS1), ACAGGCA GAAAACGGCTCCT (UGP2), GTGTAATGACAAGTTCGCCG (FZD1), and GAGAACGGTAAAGAGCGTCG (FZD7). HeLa-Cas9 cells were transduced with lentiviruses that express these sgRNAs. Mixed populations of stable cells were selected with puromycin (2.5 μg/ml) and hygromycin B (200 μg/ml). FZD1/2/7 -/cells were created by sequentially transducing FZD1 and FZD7 sgRNA lentiviruses into FZD2 -/cells and further selected in the presence of 100 pM TcdB . The mutagenesis rate in these mixed stable cells was determined by NGS ( Supplementary Table 1 ). Cytopathic assay. The cytopathic effect (cell rounding) of TcdA and TcdB was analysed using standard cell-rounding assay as previously described 1 . Briefly, cells were exposed to a gradient of TcdB and TcdB 1-1830 for 24 h. Phase-contrast images of cells were taken (Olympus IX51, ×10-20 objectives). The numbers of roundshaped and normal shaped cells were counted manually. The percentage of roundshaped cells was plotted and fitted using the Origin software.
Blocking TcdB entry into cells with CSPG4-EC and FZD2-CRD-Fc.
Recombinant proteins used for cell protection assays were pre-filtered (0.22 μm, Millipore). Toxins were pre-incubated with FZD2-CRD-Fc and/or CSPG4-EC (P1) for 30 min on ice with a toxin/protein ratio of 1:400 (except when specifically noted in the figure legend). The mixtures were added into cell culture medium and cells were analysed by the cytopathic assay. Transfection, TcdB binding to cells, and immunoblot analysis. Transient transfection of HeLa cells was carried out using PolyJet (SignaGen). Binding of TcdB to cells was analysed by exposing cells to TcdB or truncated TcdB fragments for 10 min at room temperature. Cells were washed three times with PBS and then either fixed for immunostaining analysis or harvested with RIPA buffer (50 mM Tris, 1% NP40, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, plus a protease inhibitor cocktail (Sigma-Aldrich)). Cell lysates were centrifuged and supernatants were subjected to SDS-PAGE and immunoblot analysis using the enhanced chemiluminescence method (Pierce). The full blot images are shown in Supplementary Fig. 1 . Pulldown assays. Pulldown assays were carried out using glutathione Sepharose 4B as previously described 48 . Briefly, 5 μg of GST-tagged TcdB 1831-2366 and TcdB 1501-2366 were immobilized on glutathione beads and incubated with FZD2-CRD-Fc (10 nM) for 1 h at 4 °C. Beads were then washed, pelleted, boiled in SDS sample buffer, and subjected to immunoblot analysis. BLI assay. The binding affinities between TcdB and FZD-CRDs were measured by BLI assay using the Blitz system (ForteBio). Briefly, the CRDs-Fc of FZD1, 2, 5, 7 or human IgG1 Fc (20 μg/ml) were immobilized onto capture biosensors (Dip and Read Anti-hIgG-Fc, ForteBio) and balanced with PBS. The biosensors were then exposed to TcdB or TcdB 1-1830 , followed by washing with PBS. Binding affinities (K d ) were calculated using the Blitz system software (ForteBio). Wnt signalling assay. The TOPFLASH/TK-Renilla dual luciferase reporter assay was used to detect Wnt signalling activities as previously described 51 . Briefly, 293T cells in 24-well plates were co-transfected with TOPFLASH (50 ng/well), TK-Renilla (internal control, 10 ng/well), and pcDNA3 (200 ng/well). After 24 h, cells were exposed to WNT3A (50 ng/ml) and TcdB 1114-1835 (1:8, 1:40, and 1:200 to WNT3A) in culture medium for 6 h. Cell lysates were harvested and subjected to either firefly/Renilla dual luciferase assay or immunoblot analysis for detecting phosphorylated DVL2 and LRP6. Wnt signalling activates expression of TOPFLASH luciferase reporter (firefly luciferase). Co-transfected Renilla luciferase serves as an internal control. Microtitre plate-based binding assay. Binding assays were performed on 96-well plates (EIA/RIA plate, Corning Costar) as described previously 50 . Briefly, microtiter plates were coated with 10 μg/ml rat CSPG4-EC proteins in coating buffer (0.1 M NaHCO 3 , pH 8.3) at 4 °C overnight, and then blocked with 1% bovine serum albumin in PBS for 1 h. Plates were then incubated with the indicated proteins for 1 h in PBS. Wells were washed three times with PBS plus 0.05% Tween-20 at room temperature. One-step Turbo TMB (ThermoFisher Scientific) was used as the substrate, and absorbance at 450 nm was measured with a microplate reader. Organoid culture, knockdown, and TcdB challenge assay. Crypt isolation from wild-type or FZD7 -/mouse colon was carried out as previously described, and organoids were expanded as spheroid cultures using conditioned medium 52 . Except for wild-type organoids used for Wnt signalling inhibition assay, CHIR99021 (3 μM) was also added to the medium 39 . Five days after passaging, organoids were re-suspended with Cell Recovery Solution (ThermoFisher Scientific) and mechanically fragmented. Fragments were transduced with adenoviruses expressing shRNA for FZD1, FZD2, or a control shRNA sequence using medium supplemented with Nicotinamide (10 mM, Sigma), Polybrene (8 μg/ml, Sigma), and Y-27632 (10 μM, Sigma), washed, and plated in growth factor-reduced Matrigel (Corning) 53 . Three days following viral transduction, organoids were challenged with TcdB by adding the toxin into the medium. Viability of organoids was quantified after 72 h. Wnt signalling inhibition in wild-type colon organoids. TcdB 1114-1835 was added into the culture medium of wild-type colon organoids. For rescue experiments, 5 μM CHIR99021 was also added to the medium. The medium was changed every 48 h with the constant presence of TcdB 1114-1835 and/or CHIR99021. Viability of cells was analysed after 6 days.
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Generating FZD1 and FZD2-knockdown adenovirus. All shRNAs were purchased from Sigma (MISSION shRNA library). The knockdown efficiency was validated as described in Extended Data Fig. 8c, d. shRNA sequences showing the highest efficiency were selected to generate adenoviruses. Adenoviruses expressing a control shRNA (5′-CTGGACTTCCAGAAGAACA-3′), shRNAs against mouse FZD1 (shRNA#2: 5′-TGGTGTGCAACGACAAGTTTG-3′), or FZD2 (shRNA#5: 5′-CGCTTCTCAGAGGACGGTTAT-3′) were constructed using the Block-it U6 adenoviral RNAi system (Life Technologies), followed by viral packaging and multiple rounds of amplification in 293A cells (Life Technologies). Viability assay for colonic organoids. The viability of colonic organoids was assessed using the MTT assay as previously described 54 . Briefly, the MTT solution was added to the organoid culture (500 μg/ml). After incubation at 37 °C for 2 h, the medium was discarded. For each well (containing 20 μl of Matrigel, in a 48-well plate), 60 μl of 2% SDS solution was added to solubilize the Matrigel (1 h, 37 °C), followed by the addition of 300 μl of dimethylsulfoxide (DMSO) to solubilize reduced MTT (2 h, 37 °C). The absorbance at 562 nm was measured on a microplate reader. Twenty microlitres of Matrigel without organoids was used as blank control. Normal organoids without exposure to toxins were considered as 100% viable. IHC, immunofluorescence and histology analysis. Colons from adult mice (C57BL/6 strain (purchased from The Jackson Laboratory, #000664), 10-12 weeks old, both male and female mice were used and randomly distributed into experimental groups) were dissected out and subjected to cryosectioning into sections 8-10 μm thick. Colonic sections were fixed in cold acetone for 5 min and then washed three times with PBS. The colonic sections were then blocked with 5% goat serum in PBS for 30 min at room temperature and incubated with primary antibodies overnight (anti-TcdB: 1:600; anti-FZDs: 1:250; rabbit anti-CSPG4: 1:250), followed with biotinylated goat anti-chicken or rabbit IgG secondary antibodies (1:200, Vector Laboratory) for 1 h at room temperature. The sections were then incubated with horseradish peroxidase (HRP)-conjugated streptavidin (1:500, DAKO) for 30 min. Immunoreactivity was visualized as red colour with 3-amino-9-thyl carbazole (DAKO). Cell nuclei were labelled blue with Gill's haematoxylin (1:3.5, Sigma). Frozen human colon tissue slides were purchased from BioChain Institute and subjected to IHC analysis. Immunofluorescence analysis of claudin-3 and ZO-1 was carried out using mouse colon tissues fixed in 10% formalin and embedded in paraffin (anti-claudin-3: 1:100; anti-ZO-1: 1:100). Confocal images were captured with the Ultraview Vox Spinning Disk Confocal System. Histology analysis was carried out with H&E staining of paraffin-embedded sections. Stained sections were coded and scored by observers blinded to experimental groups, based on disruption of the colonic epithelium, inflammatory cell infiltration and oedema, on a scale of 0 to 3 (mild to severe). No statistical methods were used to predetermine sample size. Competition assays in colonic tissues with recombinant proteins. All procedures were conducted in accordance with the guidelines approved by the Boston Children's Hospital Institutional Animal Care and Use Committee (IACUC) (#3028). TcdB (40 nM) was pre-incubated with either human IgG1-Fc or FZD2-Fc (2.4 μM) for 30 min on ice. To generate the ex vivo colon segments, mice (C57BL/6, 6-8 weeks, both male and female mice were used, repeated three times, each time four mice per group, the experiments were not randomized or blinded) were euthanized and the colon exposed via laparotomy. A segment in the ascending colon (~2 cm long) was sealed by tying both ends with silk ligatures. The toxin samples (40 μl) were injected through an intravenous catheter into the sealed colon segment. The injection site was then sealed with a haemostat. The colon was covered with PBS-soaked gauze for 2 h, then excised and its lumen flushed with PBS three times, and subjected to IHC analysis. Colon loop ligation assay. All procedures were conducted in accordance with the guidelines approved by the Boston Children's Hospital IACUC (#3028). Wild-type or FZD7 -/mice (The Jackson Laboratory, #012825, strain B6;129-Fzd7 tm1.1Nat /J, 6-8 weeks old, sample size indicated in Fig. 5f , g, both male and female mice were used, the experiments were not randomized or blinded) were anaesthetized following overnight fasting. A midline laparotomy was performed to locate the ascending colon and seal a ~2 cm loop with silk ligatures. Two micrograms of TcdB 1-1830 in 80 μl of normal saline or 80 μl of normal saline were injected through an intravenous catheter into the sealed colon segment, followed by closing the wounds with stitches. Mice were allowed to recover. After 8 h, mice were euthanized and the ligated colon segments were excised, weighed, and measured. The colon segments were fixed, paraffin-embedded, sectioned, and subjected to either H&E staining for histological score analysis or immunofluorescent staining for claudin-3 and ZO-1. UGP2_sg6
Relative abundance (%) Figure 3 | Assessing the sensitivity of HeLa knockout cells to TcdB and TcdB 1-1830 . a, b, HeLa-Cas9 cells with the indicated genes mutated via CRISPR-Cas9, as well as wild-type (WT) Hela-Cas9 cells, were exposed to TcdB (a) or TcdB 1-1830 (b) for 24 h. The percentages of rounded cells were quantified and plotted (error bars indicate mean ± s.d., three independent experiments). c, HeLa knockout cells were exposed to TcdB or TcdB 1-1830 for 3 h. Cell lysates were subjected to immunoblot analysis for RAC1 and non-glucosylated (gluc.) RAC1. UGP2 −/− cells retained high levels of non-glucosylated RAC1 after exposure to TcdB or TcdB . CSPG4 −/− cells retained high levels of non-glucosylated RAC1 after exposure to TcdB. FZD2 −/− and EMC4 −/− cells showed slightly higher levels of non-glucosylated RAC1 compared to wild-type cells after exposure to TcdB . Representative blots are one from two independent experiments. cells were transfected with 1D4-tagged FZD1, 2, 5, 7 and 9. Cells were exposed to TcdB (10 nM, 10 min), washed, fixed, permeabilized and subjected to immunostaining analysis. Scale bar, 20 μm. One of three independent experiments is shown. b, The CRD domains of human FZD1 (residues 102-235), FZD2 (residues 25-158) and FZD7 (residues 35-168) were aligned using the Vector NTI software. c, FZD7-CRD, but not FZD8-CRD, when expressed on the surface of CSPG4 −/− cells via a GPI anchor, mediated binding of TcdB (10 nM, 10 min) to cells. One of three independent experiments is shown. d, Wild-type (WT) HeLa cells, FZD1/2/7 −/− cells, and CSPG4 −/− cells were exposed to TcdA and subjected to cytopathic cell-rounding assay. No reduction in sensitivity to TcdA was observed for FZD1/2/7 −/− cells or CSPG4 −/− cells, suggesting that TcdA does not use FZD1/2/7 or CSPG4 as its receptors (error bars indicate mean ± s.d., two independent experiments). e, f, Representative binding/dissociation curves for TcdB binding to Fc-tagged CRDs of FZD1, 2, 5 and 7 (e), and for TcdB 1-1830 binding to FZD2-CRD-Fc (f). Binding parameters are listed in Supplementary Table 3 . Representative curves are from one of three independent experiments. g, Wild-type and EMC4 −/− cells were transfected with 1D4-tagged FZD1, 2 or 7. Cell lysates were subjected to immunoblot analysis. Expression of FZD1, 2 and 7 are reduced in EMC4 −/− cells compared to wild-type cells (n = 6, *P < 0.005, one-way ANOVA). Representative blots are from one of three independent experiments. h, Expression levels of CSPG4 in EMC4 −/− cells is similar to those in wild-type cells, suggesting that EMC is not required for singlepass transmembrane proteins. One of three independent experiments is shown. cells transfected with the indicated constructs were exposed to TcdB in medium for 10 min. Cell lysates were collected and subjected to immunoblot analysis. Expression of PVRL3 was confirmed using an anti-PVRL3 antibody. Transfection of FZD2, but not PVRL-3, increased binding of TcdB to CSPG4 −/− cells. One of three independent experiments is shown. b, Cells were challenged with TcdB (300 pM). Ectopic expression of PVRL3 failed to restore the sensitivity of CSPG4 −/− HeLa cells towards TcdB, while expression of FZD2 restored entry of TcdB and resulted in rounding of transfected cells. Co-transfected GFP marked transfected cells. Scale bar, 50 μm. One of three independent experiments is shown. c, Recombinant extracellular domain of PVRL3 (PVRL3-EC) did not reduce TcdB entry into Caco-2 cells, analysed by the cytopathic cell-rounding assay. In contrast, FZD2-CRD prevented entry of TcdB into Caco-2 cells. Scale bar, 50 μm. One of three independent experiments is shown.
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Extended Data Figure 8 | Colonic organoids showed similar levels of sensitivity to TcdB and TcdB 1-1830 , and validation of FZD1 and FZD2 knockdown efficiency. a, Colonic organoids were cultured from wild-type mice. They were exposed to a gradient of TcdB or TcdB 1-1830 . Viability of organoids was quantified using the MTT assay. TcdB and TcdB showed similar IC 50 values, suggesting that wild-type organoids are equally susceptible to TcdB and TcdB 1-1830 (n = 8, error bars indicate mean ± s.d., two independent experiments). NS, not significant. b, Immunoblot analysis of CSPG4 expression in mouse brain, colonic organoids, mouse whole colon tissue, and isolated mouse colonic epithelium (200 μg cell/ tissue lysates). The colonic epithelium was isolated from colon tissues by EDTA treatment (10 mM, 2 h at 4 °C). One of three independent experiments is shown. c, d, shRNA sequences targeting FZD1 and FZD2 were validated by measuring knockdown efficiency of transfected 1D4tagged FZD1 and FZD2 in 293T cells. shRNAs marked with asterisks (shRNA2 for FZD1 and shRNA5 for FZD2) were used to generate adenoviruses. Actin served as the loading control. One of two independent experiments is shown. 
